CORE--BIOCHEMISTRY AND BIOTECHNOLOGY

核心--生物化学与生物技术

• 批准号: 7310499
• 负责人: Robert C Young
• 金额: $ 25.02万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7310499
• 关键词: biochemistry; biomedical facility; biotechnology; mass spectrometry; neoplasm /cancer; nucleic acid chemical synthesis; polymerase chain reaction; proteomics

The Biochemistry and Biotechnology Facility (BBF) makes available to Fox Chase Cancer Center (FCCC) investigators a group of state-of-the-art technologies for the identification, characterization, and utilization of genes, polymorphisms, transcripts, proteins; and peptides. The four components of BBF are all important and synergistic. DMA Synthesis delivers error-free oligonucleotides, regular, modified, or fluorescent probes, overnight with full quality control, Quantitative Real-time PCR provides high sensitivity and accuracy gene expression quantitation and distinguishes regulation by alternate transcripts. Mass Spectrometry identifies the components of protein complexes and supports biochemical, biophysical, and drug research. Proteomics reveals the global protein changes and modifications in response to disease states or drug treatments and discovers secondary targets of cancer-causing mutations. Anthony T. Yeung, Ph.D., (Biomolecular Structure and Function) directs BBF to provide uniformly high quality products at the cutting edge of performance. This is accomplished by proactive user interactions, and external collaborations with the leaders in each discipline. The Facility is used by 53 peer-reviewed investigators with 130 grants involving all three FCCC Divisions. About 95% of its use is by investigators with peer-reviewed funding. During the last grant period, demands on DNA synthesis (700 oligonucleotides per month by 2003) and Mass Spectrometry (about 22 projects in 2003) have both doubled. In addition, new services of Quantitative Real-time PCR and Proteomics have been developed in BBF because they are critical technologies for cancer research and are used by 13 and 7 investigators, respectively. In 2003, DNA Synthesis has contributed to 48 peer-reviewed, funded investigators, Quantitative Real-time PCR, 14; Mass Spectrometry, 23; and Proteomics, 7. BBF personnel have in-depth understanding of the science of the users and facilitate their research as highly integrated tools and participants of these research programs.

生物化学和生物技术设施（BBF）提供福克斯大通癌症 中心（FCCC）调查了一组最先进的识别技术， 基因、多态性、转录物、蛋白质和肽的表征和利用。BBF的四个组成部分都是重要的和协同的。DMA合成提供无错误的寡核苷酸，常规，修饰或荧光探针，过夜，具有完全的质量控制，定量实时PCR提供高灵敏度和准确性的基因表达定量，并通过替代转录本区分调控。质谱鉴定蛋白质复合物的组分，并支持生物化学，生物物理和药物研究。 蛋白质组学揭示了响应疾病状态或药物治疗的全局蛋白质变化和修饰，并发现了致癌突变的次要靶点。安东尼·T杨博士，（生物分子结构和功能）指导BBF在性能的最前沿提供均匀的高质量产品。这是通过主动的用户交互以及与每个学科领导者的外部合作来实现的。53名经过同行审查的调查员使用了该基金，130笔赠款涉及气候变化框架公约所有三个司。大约95%的使用是由研究人员与同行评审的资金。在上一个赠款期间，对DNA合成（到2003年每月700个寡核苷酸）和质谱分析（2003年约22个项目）的需求都翻了一番。此外，BBF还开发了定量实时PCR和蛋白质组学的新服务，因为它们是癌症研究的关键技术，分别有13名和7名研究人员使用。2003年，DNA合成为48名同行评审的资助研究人员做出了贡献，定量实时PCR，14;质谱，23;和蛋白质组学，7。BBF人员对用户的科学有深入的了解，并作为这些研究计划的高度集成工具和参与者促进他们的研究。